NASDAQ
CCCC

C4 Therapeutics Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

C4 Therapeutics Inc Stock Price

Vitals

Today's Low:
$2.22
Today's High:
$2.34
Open Price:
$2.32
52W Low:
$2.85
52W High:
$13.235
Prev. Close:
$2.37
Volume:
434411

Company Statistics

Market Cap.:
$167.80 million
Book Value:
5.351
Revenue TTM:
$27.20 million
Operating Margin TTM:
-494.07%
Gross Profit TTM:
$-86745000
Profit Margin:
0%
Return on Assets TTM:
-18.43%
Return on Equity TTM:
-41.89%

Company Profile

C4 Therapeutics Inc had its IPO on 2020-10-02 under the ticker symbol CCCC.

The company operates in the Healthcare sector and Biotechnology industry. C4 Therapeutics Inc has a staff strength of 146 employees.

Stock update

Shares of C4 Therapeutics Inc opened at $2.32 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $2.22 - $2.34, and closed at $2.26.

This is a -4.64% slip from the previous day's closing price.

A total volume of 434,411 shares were traded at the close of the day’s session.

In the last one week, shares of C4 Therapeutics Inc have slipped by -21.53%.

C4 Therapeutics Inc's Key Ratios

C4 Therapeutics Inc has a market cap of $167.80 million, indicating a price to book ratio of 1.2079 and a price to sales ratio of 8.146.

In the last 12-months C4 Therapeutics Inc’s revenue was $27.20 million with a gross profit of $-86745000 and an EBITDA of $-132477000. The EBITDA ratio measures C4 Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, C4 Therapeutics Inc’s operating margin was -494.07% while its return on assets stood at -18.43% with a return of equity of -41.89%.

In Q1, C4 Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 50.9%.

C4 Therapeutics Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-2.68 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into C4 Therapeutics Inc’s profitability.

C4 Therapeutics Inc stock is trading at a EV to sales ratio of 3.2847 and a EV to EBITDA ratio of -1.5407. Its price to sales ratio in the trailing 12-months stood at 8.146.

C4 Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$396.04 million
Total Liabilities
$39.38 million
Operating Cash Flow
$0
Capital Expenditure
$589000
Dividend Payout Ratio
0%

C4 Therapeutics Inc ended 2024 with $396.04 million in total assets and $0 in total liabilities. Its intangible assets were valued at $396.04 million while shareholder equity stood at $262.47 million.

C4 Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $39.38 million in other current liabilities, 5000.00 in common stock, $-430670000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $49.48 million and cash and short-term investments were $305.03 million. The company’s total short-term debt was $7,114,000 while long-term debt stood at $8.62 million.

C4 Therapeutics Inc’s total current assets stands at $278.45 million while long-term investments were $34.71 million and short-term investments were $220.85 million. Its net receivables were $528000.00 compared to accounts payable of $1.03 million and inventory worth $0.

In 2024, C4 Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $589000.

Comparatively, C4 Therapeutics Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$2.26
52-Week High
$13.235
52-Week Low
$2.85
Analyst Target Price
$20.91

C4 Therapeutics Inc stock is currently trading at $2.26 per share. It touched a 52-week high of $13.235 and a 52-week low of $13.235. Analysts tracking the stock have a 12-month average target price of $20.91.

Its 50-day moving average was $3.3 and 200-day moving average was $4.61 The short ratio stood at 6.11 indicating a short percent outstanding of 0%.

Around 1132% of the company’s stock are held by insiders while 8119.1% are held by institutions.

Frequently Asked Questions About C4 Therapeutics Inc

The stock symbol (also called stock or share ticker) of C4 Therapeutics Inc is CCCC

The IPO of C4 Therapeutics Inc took place on 2020-10-02

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$37.3
-1.71
-4.38%
$306.95
-36
-10.5%
$414.65
-24.95
-5.68%
$0.45
0
0%
$24.38
0.23
+0.95%
$1092.5
55.55
+5.36%
$6.51
0.33
+5.34%
$0.22
0.01
+2.8%
NXTDIGITAL LIMITED (NXTDIGITAL)
$130.65
-2.65
-1.99%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Address

490 Arsenal Way, Watertown, MA, United States, 02472